| |
The Experts in Animal Health |
|
|
|
|
|
|
|
|
|
|
|
With today’s tight competition for top animal health talent, you need every advantage to attract the best people. There’s a reason Animal Health Jobs is the premier job board for the animal health and animal nutrition industry. With our tiered packages, you choose the level of service that’s right for your company. We accept roles across animal health, in marketing, business development, communications, technical services, sales, R&D and more.
|
|
|
|
We accept roles across animal health, in marketing, business development, communications, technical services, sales, R&D and more. Whether you need a cat, dog, horse, pig, cow or poultry person, you’ll find the best ones here. If you need top talent, there’s no time to wait. Register your company or call us at 1-252-203-0033.
www.animalhealthjobs.com
|
|
|
|
Company Earnings Releases - Merck announced financial
results for the second quarter of 2024. Animal Health sales were $1,482
million, an increase of 2% (+6% currency adjusted). (company press release)
- Colgate-Palmolive
Company reported results for second quarter 2024. Hill's Pet Nutrition net sales were $1,114 million, an increase of
5%. Segment operating profit was $235 million, an increase of 23%. (company press release)
- Cencora
reported results for the fiscal third quarter ended June 30, 2024. Revenues for
MWI Animal Health were $1,370
million, an increase of 4%. (Seekingalpha)
- Neogen Corporation announced the results
of the fiscal year ended May 31, 2024. Revenues were $924 million, an increase
of 12% compared to the prior year. Net loss was $(9.4) million compared to net
loss of $(22.9) million in the prior year. Revenues for the Animal Safety segment
were $268.9 million, a decrease of 2.5% compared to the prior year. (company press release)
- Hester Biosciences reported results for
the full year ended March 31, 2024. Revenue was INR 3.11 billion ($37 million),
up 12% from FY 2023). Net income was INR
188.9m ($2.26 million), down 29% from FY 2023. (simplywall.st)
- Pets at Home Group reported results for
the first quarter of the 2024-25 financial year. consumer revenues increased
1.5% to GBP 577 million ($739 million). Retail revenues were down slightly, but
the company’s like-for-like Vet Group revenues were up by 13%. (Vettimes)
|
|
|
|
Southwest Veterinary
Symposium
SWVS 2024 Fort Worth!
Fort Worth, Texas – Fort
Worth Convention Center
September 26-29, 2024
Join Us! Register now for the best continuing
education in the Southwest!
Southwest
Veterinary Symposium — a partnership of the Arkansas, Louisiana, New Mexico,
Oklahoma, and Texas Veterinary Medicine Associations which provides continuing
education for veterinary professionals. Join us this September in Fort Worth,
Texas, where you can learn about the latest innovations and products while
exploring our exhibit hall, network with other veterinary professionals, and
choose from more than 400+ hours of quality CE/RACE-approved sessions.
www.swvs.org |
|
|
|
Company News Releases - Dechra and Akston Biosciences Corporation
announced Dechra’s purchase of all Akston’s interests in the companies’ dog and
cat long-acting insulin programs. The companies signed a licensing and supply
agreement in August 2019 for the co-development and commercialization of a
long-acting insulin for the treatment of diabetes in dogs, which Akston
invented, and a similar agreement for the treatment of diabetes in cats in
February 2021. Financial terms were not disclosed. (company press release)
- Vetoquinol announced that the FDA
approved a three-year expiration date for Clevor (ropinirole ophthalmic
solution) when stored in its original packaging. The extension increases its
previous expiration date by 12 months to 36 months from the date of
manufacture. (company press release)
- The
FDA announced the approval of Bimeda
Animal Health's MoxiSolv Injection (generic moxidectin) for use in cattle. (FDA)
- Huvepharma has entered into a
sales and marketing agreement with ADM,
through which three ADM feed additives will be made available immediately to
the Huvepharma's ruminant product line. (Beef Magazine)
- Bionote USA announces its
partnership with MWI Animal Health for
the distribution of Bionote products including the Vcheck line of quantitative,
in-clinic analyzers and biomarker tests and its new standalone, one-step rapid
test for detecting Canine Heartworm. (company
press release)
- Innocan Pharma Corporation announced
that the FDA's Center for Veterinary Medicine (CVM) has granted the Company a
sponsor fee waiver and assigned an Investigational New Animal Drug (INAD)
number for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product, a proprietary
drug delivery platform designed to provide prolonged-release CBD for chronic
pain and well-being management in animals.
(prnewswire)
- Oral Biolife announced a strategic
partnership with a global animal health company to develop a treatment for
periodontal disease in companion animals utilizing the unique properties of
piezo materials. (einnews.com)
- GERMANY
Private equity firm Inflexion announced plans to invest an undisclosed amount in Tierarzt Plus Partner (TPP), a German
group of 100 veterinary practices. TPP is Inflexion's fourth investment in the
animal health sector. (pehubeurope.com)
- TAIWAN
Protect Animal Health (PAH) and DotBio announced a strategic
collaboration to develop innovative therapeutic antibody discovery platform
technologies and a therapeutic antibody pipeline specifically tailored for dogs
and cats. (geneonline.com)
- ITALY Conad,
one of the largest supermarket chains in Italy, announced that customers who
are part of its loyalty scheme, Carta Insieme, will be able to access basic and
specialist veterinary care services through a partnership with BluVet, a veterinary service provider
with a network of 30 veterinary clinics and hospitals across Italy. (Globalpets)
|
|
|
|
Animal Health Stock Price Tracker |
|
|
|
|
|
Animal Health News
- US - STAFF EDUCATION The American Heartworm Society has released
Heartworms Unraveled, a series of five video-based training modules created to
provide comprehensive staff education on heartworm biology, heartworm life
cycle and epidemiology; heartworm testing; heartworm prevention; heartworm
treatment; and feline heartworm disease for their clinical staff members. (Vet Advantage)
- WORLD
The International Livestock Research Institute (ILRI) welcomed Fabian
Kausche as new Deputy Director General of Research and Innovation. Kausche was
the global head of research and development for three of the top seven global
animal health companies and subsequently served as chairman of the board for
PetMedix, a startup that was recently acquired by Zoetis. (association press release)
- US - DRUG REGULATION The FDA has announced in the Federal Register
the fiscal year (FY) 2025 fee rates and payment procedures for animal drugs
subject to user fees under the Animal Drug and Animal Generic Drug User Fee
Amendments of 2023. Click here for details. (FDA)
- US - LIVESTOCK REGULATION The USDA has extended the 60-day comment
period for their latest Packers and Stockyards proposed rule, "Fair and
Competitive Livestock and Poultry Markets," from Aug. 27, 2024 to Sept.
11, 2024. The rule seeks to provide clarity regarding the interpretation of
“unfair” under section 202(a) of the P&S Act to further the understanding
of what conduct the P&S Act prohibits. If finalized, USDA said it would
provide a workable guideline on how the prohibitions on unfair practices will operate
and be enforced. Click here for details. (Feedstuffs)
- US - ANTIMICROBIAL GUIDELINES The American
Veterinary Medical Association board of directors approved policy revisions on
the judicious therapeutic use of antimicrobials. The AVMA’s Committee on
Antimicrobials recommended better alignment with the third core principle of
antimicrobial stewardship in veterinary medicine: “Select and use antimicrobial
drugs judiciously.” (Todays Veterinary Business)
|
|
|
|
Brakke Consulting Viewpoint
As
most of you know, it’s quarterly earnings reporting time. I’ll admit I was a little down in the dumps
earlier this week after reading a few articles in the Wall Street Journal about companies slow or no growth. How was the 2nd quarter for animal health
companies going to turn out, I wondered.
Two
weeks ago, Boehringer Ingelheim reported 1H growth of 1% (CC) but Virbac
reported 1H growth of 11.3% (CC). Last
week, Nestle reported organic growth of 3.8% for its Nestle Purina PetCare
business. This week, Merck reported that
its animal health business grew 6% (CC) in 2Q (up from 4% in 1Q) with the
livestock business growing 11% in the quarter and the companion animal business
growing 1%. Also, Cencora’s MWI animal
health business reported 6.7% growth over the last three quarters, but only 4%
for the last quarter. Finally,
Colgate-Palmolive’s Hills Pet Nutrition reported organic growth in 2Q of 6.1%
and 1H growth of 5.2%.
IDEXX
and Zoetis report next week and Elanco after that, so we will have a better
idea of industry growth this year very soon.
What is apparent is that there is softness in the companion animal
parasiticide segment, which we will comment on after a few more companies
report. Even with this softness, it
looks like the animal health industry is on a mid-single digit growth
trajectory. Again.
Bob Jones
|
|
|
|
Your View
Last week, we asked you about small start-up companies and their
exit plans. Seems like this was as easy
as a layup – or a Caitlyn Clark 3-pointer.
Over 90% of you said less than half had an exit plan, which according to
several research studies, is the correct answer.
This week
In the news this week, the FDA announced the FY 2025
fees for animal drugs subject to user fees under ADUFA and AGDUFA, the latter
being for generic products. This always
makes me think of the costs and barriers of innovation in our industry. Let’s see if you can guess how many original
NADA and reactivations were subject to user fees since the current user fee
program started in FY2022 running through FY2024 (March).
|
|
|
|
|
|
|
|
Trouble
viewing this newsletter? You can view it online at www.BrakkeConsulting.com
This
electronic newsletter is the sole property of Brakke Consulting.
Any use of the contents herein should be approved by and appropriately
attributed to Brakke Consulting.
For more information about Brakke Consulting's services and
syndicated studies, visit our website at www.brakkeconsulting.com.
Brakke
Consulting
806
Green Valley Rd
Suite 200
Greensboro, NC 27408 |
|
|
|
|
|
|
.jpg)
